Eagle Pharmaceuticals, Inc. (EGRX)
OTCMKTS · Delayed Price · Currency is USD
0.650
0.00 (0.00%)
Dec 18, 2024, 4:00 PM EST

Eagle Pharmaceuticals Statistics

Total Valuation

Eagle Pharmaceuticals has a market cap or net worth of 8.47 million. The enterprise value is 65.57 million.

Market Cap 8.47M
Enterprise Value 65.57M

Important Dates

The next estimated earnings date is Friday, March 7, 2025.

Earnings Date Mar 7, 2025
Ex-Dividend Date n/a

Share Statistics

Eagle Pharmaceuticals has 13.02 million shares outstanding.

Current Share Class n/a
Shares Outstanding 13.02M
Shares Change (YoY) n/a
Shares Change (QoQ) +0.01%
Owned by Insiders (%) 11.10%
Owned by Institutions (%) 39.52%
Float 6.31M

Valuation Ratios

The trailing PE ratio is 0.71.

PE Ratio 0.71
Forward PE n/a
PS Ratio 0.03
PB Ratio 0.03
P/TBV Ratio 0.09
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 1.03, with an EV/FCF ratio of -6.98.

EV / Earnings 5.49
EV / Sales 0.25
EV / EBITDA 1.03
EV / EBIT 1.57
EV / FCF -6.98

Financial Position

The company has a current ratio of 2.16, with a Debt / Equity ratio of 0.29.

Current Ratio 2.16
Quick Ratio 1.51
Debt / Equity 0.29
Debt / EBITDA 1.14
Debt / FCF -7.71
Interest Coverage 6.85

Financial Efficiency

Return on equity (ROE) is 4.88% and return on invested capital (ROIC) is 8.46%.

Return on Equity (ROE) 4.88%
Return on Assets (ROA) 6.63%
Return on Capital (ROIC) 8.46%
Revenue Per Employee 1.92M
Profits Per Employee 89,164
Employee Count 134
Asset Turnover 0.65
Inventory Turnover 1.55

Taxes

Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -85.96% in the last 52 weeks. The beta is 0.52, so Eagle Pharmaceuticals's price volatility has been lower than the market average.

Beta (5Y) 0.52
52-Week Price Change -85.96%
50-Day Moving Average 0.73
200-Day Moving Average 3.61
Relative Strength Index (RSI) 43.38
Average Volume (20 Days) 20,209

Short Selling Information

Short Interest n/a
Short Previous Month n/a
Short % of Shares Out n/a
Short % of Float n/a
Short Ratio (days to cover) 2.08

Income Statement

In the last 12 months, Eagle Pharmaceuticals had revenue of 257.55 million and earned 11.95 million in profits. Earnings per share was 0.91.

Revenue 257.55M
Gross Profit 179.88M
Operating Income 41.71M
Pretax Income 29.17M
Net Income 11.95M
EBITDA 62.33M
EBIT 41.71M
Earnings Per Share (EPS) 0.91
Full Income Statement

Balance Sheet

The company has 15.35 million in cash and 72.45 million in debt, giving a net cash position of -57.10 million or -4.38 per share.

Cash & Cash Equivalents 15.35M
Total Debt 72.45M
Net Cash -57.10M
Net Cash Per Share -4.38
Equity (Book Value) 252.04M
Book Value Per Share 19.25
Working Capital 100.62M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -9.32 million and capital expenditures -74,000, giving a free cash flow of -9.39 million.

Operating Cash Flow -9.32M
Capital Expenditures -74,000
Free Cash Flow -9.39M
FCF Per Share -0.72
Full Cash Flow Statement

Margins

Gross margin is 69.84%, with operating and profit margins of 16.19% and 4.64%.

Gross Margin 69.84%
Operating Margin 16.19%
Pretax Margin 11.33%
Profit Margin 4.64%
EBITDA Margin 24.20%
EBIT Margin 16.19%
FCF Margin n/a

Dividends & Yields

Eagle Pharmaceuticals does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -2.21%
Shareholder Yield -2.21%
Earnings Yield 140.26%
FCF Yield -110.95%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

Eagle Pharmaceuticals has an Altman Z-Score of 3.26.

Altman Z-Score 3.26
Piotroski F-Score n/a